• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/22/21 4:01:11 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNFT alert in real time by email
    SC 13G 1 tm217530d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
    SCHEDULE 13G*/
    (Rule 13d-102)
     
    Genfit S.A.
    (Name of Issuer)
     
    Ordinary shares, nominal value €0.25 per share
    (Title of Class of Securities)
     

    372279109**

    (CUSIP Number)
     

    February 10, 2021

    Date of Event Which Requires Filing of the Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    */ The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** This CUSIP number applies to the American Depository Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “GNFT.” Each ADS represents one ordinary share. No CUSIP has been assigned to the ordinary shares.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 372279109 13G Page 2 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Advisors LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    409,024 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.1%1

     

    12.

     

     

    TYPE OF REPORTING PERSON

    IA; OO; HC

      

     

    1The percentages reported in this Schedule 13G are based upon 38,858,617 ordinary shares outstanding as of December 21, 2019 (according to the issuer’s Form 20-F as filed with the Securities and Exchange Commission on May 27, 2020). Except as described in the preceding sentence, all share numbers for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on February 22, 2021.

     

     

     

     

    CUSIP No. 372279109 13G Page 3 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Advisors Holdings LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    409,024 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.1%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    PN; HC

      

     

     

     

    CUSIP No. 372279109 13G Page 4 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    409,024 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.1%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

     

    CUSIP No. 372279109 13G Page 5 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Securities LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    33,365 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.1%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    BD, OO

      

     

     

     

    CUSIP No. 372279109 13G Page 6 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    CALC IV LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    53,153 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.1%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    PN; HC

      

     

     

     

    CUSIP No. 372279109 13G Page 7 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Securities GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    53,153 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.1%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

     

    CUSIP No. 372279109 13G Page 8 of 14 Pages  

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Kenneth Griffin

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    462,177 shares

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.2%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    IN; HC

     

     

     

     

    CUSIP No. 372279109 13G Page 9 of 14 Pages  

     

    Item 1(a)Name of Issuer

    Genfit S.A.

     

    Item 1(b)Address of Issuer’s Principal Executive Offices

    Parc Eurasanté, 885, avenue Eugène Avinée, 59120 Loos, France

     

    Item 2(a)Name of Person Filing
    This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), CALC IV LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to ordinary shares of the above-named issuer owned by Citadel Equity Fund Ltd., a Cayman Islands company (“CEFL”), Citadel Multi-Strategy Equities (Ireland) Designated Activity Company, an Ireland company (“CMSI”), Citadel Securities, and Citadel Securities (Europe) Limited, an United Kingdom limited company (“CDGE”).

     

    Citadel Advisors is the portfolio manager for CEFL and CMSI. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities and CDGE. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.

     

    The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

     

    Item 2(b)Address of Principal Business Office
    The address of the principal business office of each of the Reporting Persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603.

     

    Item 2(c)Citizenship
    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.

     

    Item 2(d)Title of Class of Securities

    Ordinary shares, nominal value €0.25 per share

     

    Item 2(e)CUSIP Number

    372279109

     

     

     

    CUSIP No. 372279109 13G Page 10 of 14 Pages  

     

    Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

    CUSIP No. 372279109 13G Page 11 of 14 Pages  

     

    Item 4Ownership

     

    A.Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC

     

    (a)Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 409,024 ordinary shares.

     

    (b)The number of shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes approximately 1.1% of the ordinary shares outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 409,024

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 409,024

     

    B.Citadel Securities LLC

     

    (a)Citadel Securities LLC may be deemed to beneficially own 33,365 ordinary shares.

     

    (b)The number of shares that Citadel Securities LLC may be deemed to beneficially own constitutes approximately 0.1% of the ordinary shares outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 33,365

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 33,365

     

    C.CALC IV LP and Citadel Securities GP LLC

     

    (a)Each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own 53,153 ordinary shares.

     

    (b)The number of shares that each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes approximately 0.1% of the ordinary shares outstanding.

     

     

     

    CUSIP No. 372279109 13G Page 12 of 14 Pages  

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 53,153

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 53,153

     

    D.Kenneth Griffin

     

    (a)Mr. Griffin may be deemed to beneficially own 462,177 ordinary shares.

     

    (b)The number of shares that Mr. Griffin may be deemed to beneficially own constitutes approximately 1.2% of the ordinary shares outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 462,177

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 462,177

     

     

     

     

    CUSIP No. 372279109 13G Page 13 of 14 Pages  

     

    Item 5Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    See Item 2 above

     

    Item 8Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9Notice of Dissolution of Group

    Not Applicable

     

    Item 10Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 372279109 13G Page 14 of 14 Pages  

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 22nd day of February, 2021.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC
         
    By: /s/ Guy Miller   By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory
         
         
    CALC IV LP   CITADEL ADVISORS HOLDINGS LP
         
    By: /s/ Guy Miller   By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory
         
         
    CITADEL SECURITIES GP LLC   CITADEL GP LLC
         
    By: /s/ Guy Miller   By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory
         
         
        KENNETH GRIFFIN
         
        By: /s/ Gregory Johnson
          Gregory Johnson, attorney-in-fact*

     

     

    *Gregory Johnson is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Jaws Acquisitions Corp. on February 1, 2021.

     

    Get the next $GNFT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNFT

    DatePrice TargetRatingAnalyst
    12/20/2021$8.00Neutral → Buy
    HC Wainwright & Co.
    9/30/2021$8.00 → $7.00Neutral
    HC Wainwright & Co.
    More analyst ratings

    $GNFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

      SC 13G/A - Genfit S.A. (0001757064) (Subject)

      2/14/24 4:00:25 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by GENFIT S.A.

      SC 13G - Genfit S.A. (0001757064) (Subject)

      5/1/23 4:00:10 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

      SC 13G/A - Genfit S.A. (0001757064) (Subject)

      2/14/22 6:28:17 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    SEC Filings

    See more
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      5/7/25 4:10:07 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      5/5/25 6:00:48 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      4/29/25 3:10:19 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Financials

    Live finance-specific insights

    See more
    • Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

      Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

      12/17/21 1:00:00 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

      Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic

      5/31/23 4:44:00 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

      Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

      12/17/21 1:00:00 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genfit upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00

      12/20/21 6:28:59 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Genfit with a new price target

      HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously

      9/30/21 6:11:01 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Genfit with a new price target

      SVB Leerink reiterated coverage of Genfit with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      4/5/21 6:31:27 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care